MediciNova
Develops in-licensed small molecules across neurodegenerative, metabolic, and fibrotic diseases.
Something off on this page? Send us feedback.
Profile
Develops in-licensed small-molecule therapeutics for serious neurodegenerative, metabolic, and fibrotic diseases. Reports service revenue from a clinical-research support arrangement rather than product sales, while its broader program set relies on two licensed molecules.
Develops in-licensed small-molecule therapeutics for serious diseases with unmet medical needs, centered on MN-166 (ibudilast) and MN-001 (tipelukast). Its clinical work spans ALS, degenerative cervical myelopathy, progressive multiple sclerosis, Long COVID, substance dependence, and metabolic and fibrotic disease. No products are approved for commercial sale.
Operates from California with legal entities in Japan, Germany, and Canada, while development focuses primarily on the U.S. market. Clinical execution relies on research institutions, government-supported studies, and outside providers rather than a large internal organization.
Builds multiple indication programs from two licensed molecules, so clinical, regulatory, supply, intellectual-property, and licensing outcomes for either compound can affect several programs. Existing license agreements include potential development milestones and future sales royalties.
Company facts
Key statistics
Year to date +7.9% · Average volume (30d) 35.7K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$0.06 | −$0.05 | +21.0% | $75.0K | $459.0K | +512.0% | 0.00% |
| May 15, 2026Q1 FY26 | −$0.06 | −$0.05 | +16.7% | $187.0K | $187.0K | 0.0% | +0.72% |
| Feb 20, 2026Q4 FY25 | −$0.10 | −$0.05 | +47.4% | $151.7K | $151.0K | −0.5% | −0.67% |
| Nov 12, 2025Q3 FY25 | −$0.08 | −$0.06 | +25.0% | — | $123.3K | — | −1.91% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $134.6K | $123.3K | $151.7K | $187.0K | $458.4K | |
| Gross profit | $0 | $18.3K | $8.0K | $51.8K | $12.6K | $317.8K | |
| Operating income | −$3.2M | −$3.6M | −$3.4M | −$3.1M | −$2.8M | −$2.5M | |
| Net income | −$2.9M | −$3.3M | −$3.1M | −$2.8M | −$2.6M | −$2.3M | |
| Diluted EPS | −$0.06 | −$0.07 | −$0.06 | −$0.05 | −$0.05 | −$0.05 | |
| Gross margin | — | 13.6% | 6.5% | 34.1% | 6.8% | 69.3% | |
| Operating margin | — | -2,679.9% | -2,741.7% | -2,038.0% | -1,516.6% | -554.3% |
Fiscal years (4-quarter sums)FY21 $4.0M · FY22 $0 · FY23 $1.0M · FY24 $0 · FY25 $409.7K
Balance sheet, Jun 30, 2026Cash & short-term investments $25.4M · Total debt $117.0K · Total assets $40.4M · Shareholders' equity $37.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 49.22M · Float 42.26M · 85.9% free float
Insiders — no current Form 4 position.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Essex Woodlands Management, Inc. | 1.11M | 2.25% | 13F | May 4, 2026 |
| BlackRock, Inc. | 706.0K | 1.43% | 13F | May 13, 2026 |
| Citigroup Inc | 635.7K | 1.29% | 13F | May 11, 2026 |
| Vanguard Capital Management LLC | 611.0K | 1.24% | 13F | May 15, 2026 |
| Geode Capital Management, LLC | 543.8K | 1.10% | 13F | May 15, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Biogen
Approved SOD1-ALS therapy and a broad-ALS pipeline entrant.
- Madrigal Pharmaceuticals
Approved MASH therapy with large commercial and trial advantages.
- Ionis Pharmaceuticals
Phase 3 FUS-ALS program targeting a genetically defined subgroup.
- Novo Nordisk (ADR)
Phase 3 MASH program backed by a global metabolic-care leader.
- AllianceBernstein
Prospective Phase 3 ALS program with masitinib.
- Amarin (ADR)
Established triglyceride-lowering therapy for overlapping metabolic patients.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| MediciNova | $1.44 | 0.00% | $70.6M | — | — | 76.7 | +241.0% |
| Biogen | $218.19 | −0.14% | $32.28B | 38.7 | 16.5 | 3.2 | +3.4% |
| Madrigal Pharmaceuticals | $533.76 | −0.02% | $12.33B | — | — | 9.6 | +71.2% |
| Ionis Pharmaceuticals | $61.05 | +0.02% | $10.15B | — | — | 11.6 | −40.7% |
| Novo Nordisk (ADR) | $45.60 | +0.00% | $202.54B | 11.2 | 18.4 | 4.0 | +0.0% |
| AllianceBernstein | $36.71 | −0.41% | $3.43B | 10.9 | 10.1 | 10.0 | +5.1% |
| Amarin (ADR) | $13.97 | 0.00% | $288.9M | — | — | 1.6 | −42.0% |
| Median | 11.2 | 16.5 | 6.8 | +1.7% |